2. Academic Validation
  3. Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

  • Haematologica. 2021 Mar 1;106(3):859-862. doi: 10.3324/haematol.2019.224535.
Franck Morschhauser 1,  Kamal Bouabdallah 2,  Stephan Stilgenbauer 3,  Catherine Thieblemont 4,  Sophie de Guibert 5,  Florian Zettl 6,  Lawrence M Gelbert 7,  Kellie P Turner 8,  Siva Rama Prasad Kambhampati 8,  Li Li 8,  Lily Q Li 8,  Sean Buchanan 8,  Susana Barriga 8,  Melissa M Bear 8,  Martin Wilhelm 9,  Georg Hess 10
Affiliations

Affiliations

  • 1 Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire, Lille, France.
  • 2 Hopital Haut-Levêque, Centre Hospitalier Regional Universitaire de Bordeaux, Pessac, France.
  • 3 Internal Medicine III, Ulm University, Ulm, Germany.
  • 4 Hemato-Oncology Department, Hôpital Saint-Louis and Diderot University, Paris, France.
  • 5 Hôpital de Pontchaillou, Rennes, France.
  • 6 Universitätsmedizin Göttingen, Göttingen, Germany.
  • 7 LMG PharmaTech, LLC., Indianapolis, Indiana, USA.
  • 8 Eli Lilly and Company, Indianapolis, Indiana, USA.
  • 9 Klinikum Nürnberg Nord, Nürnberg, Germany.
  • 10 Universitätsmedizin Mainz, Mainz, Germany.
PMID: 32381571 DOI: 10.3324/haematol.2019.224535
Figures
Products